- Home
- ELTX vs AEC Comparison
ELTX vs AEC Comparison
Compare ELTX & AEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTX
- AEC
- Stock Information
- Founded
- ELTX 2011
- AEC 1989
- Country
- ELTX United States
- AEC Canada
- Employees
- ELTX N/A
- AEC N/A
- Industry
- ELTX Biotechnology: Pharmaceutical Preparations
- AEC Real Estate Investment Trusts
- Sector
- ELTX Health Care
- AEC Real Estate
- Exchange
- ELTX Nasdaq
- AEC Nasdaq
- Market Cap
- ELTX 121.7M
- AEC 110.9M
- IPO Year
- ELTX N/A
- AEC N/A
- Fundamental
- Price
- ELTX $10.05
- AEC $9.59
- Analyst Decision
- ELTX Strong Buy
- AEC
- Analyst Count
- ELTX 2
- AEC 0
- Target Price
- ELTX $11.00
- AEC N/A
- AVG Volume (30 Days)
- ELTX 68.1K
- AEC 265.5K
- Earning Date
- ELTX 11-12-2025
- AEC 01-01-0001
- Dividend Yield
- ELTX N/A
- AEC N/A
- EPS Growth
- ELTX N/A
- AEC N/A
- EPS
- ELTX N/A
- AEC N/A
- Revenue
- ELTX N/A
- AEC N/A
- Revenue This Year
- ELTX N/A
- AEC N/A
- Revenue Next Year
- ELTX N/A
- AEC N/A
- P/E Ratio
- ELTX N/A
- AEC N/A
- Revenue Growth
- ELTX N/A
- AEC N/A
- 52 Week Low
- ELTX $4.05
- AEC $6.00
- 52 Week High
- ELTX $12.62
- AEC $12.49
- Technical
- Relative Strength Index (RSI)
- ELTX 39.00
- AEC N/A
- Support Level
- ELTX $10.37
- AEC N/A
- Resistance Level
- ELTX $10.73
- AEC N/A
- Average True Range (ATR)
- ELTX 0.51
- AEC 0.00
- MACD
- ELTX -0.09
- AEC 0.00
- Stochastic Oscillator
- ELTX 9.49
- AEC 0.00
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.